MRONJ risk of adjuvant bisphosphonates in early stage breast cancer

被引：17

作者：

Patel, V. ^{[1
]}

Mansi, J. ^{[2
]}

Ghosh, S. ^{[2
]}

Kwok, J. ^{[1
]}

Burke, M. ^{[3
]}

Reilly, D. ^{[3
]}

Nizarali, N. ^{[3
]}

Sproat, C. ^{[1
]}

Chia, K. ^{[2
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Dept Oral Surg, Fl 23,Tower Wing, London SE1 9RT, England

[2] Guys & St Thomas NHS Fdn Trust, Dept Oncol, Fl 23,Tower Wing, London SE1 9RT, England

[3] Guys & St Thomas NHS Fdn Trust, Sedat & Special Care, Fl 23,Tower Wing, London SE1 9RT, England

来源：

BRITISH DENTAL JOURNAL | 2018年 / 224卷 / 02期

关键词：

ZOLEDRONIC ACID; PREVENTIVE MEASURES; OSTEONECROSIS; JAW; IMPLEMENTATION; MANAGEMENT; REDUCE;

D O I：

10.1038/sj.bdj.2017.1039

中图分类号：

R78 [口腔科学];

学科分类号：

1003 ;

摘要：

Medication-related osteonecrosis of the jaw (MRONJ) has most commonly been associated with bisphosphonates. The routine uses of these drugs are now well established predominantly in metastatic cancer with bone involvement, multiple myeloma, hypercalcaemia, osteoporosis and Paget's disease. Recently, however, the use of bisphosphonates in early breast cancer has shown a reduction in breast cancer recurrence and breast cancer deaths. This new indication for their use approximates to a further 20,000 women per year in the UK being prescribed bisphosphonates. In this article, we consider the dental impact of this new use of bisphosphonates, report on the rates of MRONJ seen in early breast cancer bisphosphonate trials and discuss strategies aimed at minimising the risk of bisphosphonate-exposed patients developing MRONJ.

引用

页码：74 / 79

页数：6

共 50 条

[31] Optimizing adjuvant chemotherapy in early-stage breast cancer
Perez, Edith
Muss, Hyman B.
ONCOLOGY-NEW YORK, 2005, 19 (14): : 1759 - 1767
[32] Adjuvant Hormonal Therapy for Early-Stage Breast Cancer
Burstein, Harold J.
Griggs, Jennifer J.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 19 (03) : 639 - +
[33] Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer
Coleman, Robert
CLINICAL BREAST CANCER, 2007, 7 : S29 - S35
[34] The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany
Fick, Eva-Maria
Katalinic, Alexander
Waldmann, Annika
CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 747 - 756
[35] Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Allan Lipton
Breast Cancer Research and Treatment, 2010, 122 : 627 - 636
[36] INFLUENCE OF ADJUVANT BISPHOSPHONATES AND DENOSUMAB ON BREAST CANCER OUTCOMES
Coleman, R.
OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S93 - S93
[37] Optimal Use of Adjuvant Bisphosphonates and Breast Cancer Reply
Dhesy-Thind, Sukhbinder
Fletcher, Glenn G.
Clemons, Mark
Van Poznak, Catherine
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) : 2720 - +
[38] Adjuvant Bisphosphonates in Postmenopausal Women with Breast Cancer in Lanarkshire
Park, D.
Abdullah, T.
CLINICAL ONCOLOGY, 2019, 31 (07) : E113 - E113
[39] Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Lipton, Allan
BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (03) : 627 - 636
[40] Adjuvant bisphosphonates in breast cancer: has the time come?
Gagliato, Debora
Chavez-MacGregor, Mariana
BREAST CANCER MANAGEMENT, 2013, 2 (04) : 327 - 337

← 1 2 3 4 5 →